New anticancer agents: hormones made within the heart

Area of Science:

• Cardiovascular Endocrinology
• Cancer Biology
• Molecular Oncology

Background:

• The heart functions as an endocrine gland, producing the atrial natriuretic peptide (ANP) prohormone.
• The ANP prohormone yields four distinct peptide hormones with potential therapeutic applications.

Purpose of the Study:

• To investigate the anticancer efficacy of four cardiac-derived peptide hormones.
• To elucidate the molecular mechanisms underlying their cytotoxic effects on cancer cells.

Main Methods:

• In vitro cell culture studies using human cancer cell lines (pancreatic, breast, colon, prostate, kidney, ovarian, lung).
• In vivo studies in athymic mice bearing human tumor xenografts.
• Analysis of the Rat sarcoma (RAS)-mitogen activated protein kinase kinase 1/2 (MEK1/2)-extracellular signal related kinase 1/2 (ERK1/2) signaling pathway.

Main Results:

• Cardiac hormones reduced cancer cell viability by up to 97% in vitro within 24 hours.
• In vivo, these hormones eliminated up to 80% of pancreatic adenocarcinomas, two-thirds of breast cancers, and 86% of small-cell lung cancers.
• The hormones inhibited key signaling proteins including Ras, MEK1/2, ERK1/2, and MAPK9 (c-Jun-N-terminal kinase 2), blocking mitogen-induced signaling.

Conclusions:

• Four peptide hormones synthesized by the heart exhibit potent, broad-spectrum anticancer activity.
• Their mechanism involves the targeted inhibition of critical cancer cell proliferation pathways (RAS-MAPK cascade).
• These hormones are selectively cytotoxic to cancer cells, sparing normal cells, suggesting therapeutic potential.